» Articles » PMID: 30928567

Substance Use Disorders in Pregnancy: Clinical, ethical, and Research Imperatives Of the opioid Epidemic: a Report of a Joint Workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American...

Citing Articles

Septo-optic Dysplasia in a Patient With Increased Socioeconomic Needs: A Case Report.

Mohiuddin A, Taweel A, Taha W, Farrow S Cureus. 2025; 17(2):e78479.

PMID: 40062035 PMC: 11885175. DOI: 10.7759/cureus.78479.


Outpatient tapering of buprenorphine in opioid use disorder pregnancies may improve neonatal outcomes.

Shah D, Adelli R, Chroust A, Lewis N, Olsen M J Perinatol. 2025; .

PMID: 39929991 DOI: 10.1038/s41372-025-02211-6.


Evaluating maternal drug use disparities, risk factors and outcomes in Northeast Arkansas: a pre, during, and post-COVID-19 pandemic analysis.

Gomez Pomar E, Berryhill J, Bhattacharyya S BMC Public Health. 2025; 25(1):509.

PMID: 39920626 PMC: 11806827. DOI: 10.1186/s12889-025-21636-4.


Implementing Best Practice When Screening Birthing People for a Substance Use Disorder.

Kaufman S, Suplee P, Campbell-Oparaji D, Blumenfeld J J Midwifery Womens Health. 2024; 69(6):952-957.

PMID: 39444170 PMC: 11622360. DOI: 10.1111/jmwh.13697.


Physiologically based pharmacokinetic modeling of long-acting extended-release naltrexone in pregnant women with opioid use disorder.

Shenkoya B, Gopalakrishnan M, Eke A CPT Pharmacometrics Syst Pharmacol. 2024; 13(11):1939-1952.

PMID: 39380562 PMC: 11578127. DOI: 10.1002/psp4.13252.